Item 7.01 Regulation FD Disclosure” and in Exhibit 99.1 is intended to be furnished pursuant to
Item 7.01. Such information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference into any
filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. The furnishing of this information pursuant to Item 7.01 shall not be deemed an admission by Salix as to the materiality of
such information.
| Item 9.01. |
Financial Statements and Exhibits. |
|
|
|
| Exhibit No. |
|
Description |
| 99.1 |
|
Press release dated August 18, 2008. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
SALIX PHARMACEUTICALS, LTD. |
|
|
| Date: August 18, 2008 |
|
|
|
|
/s/ Adam C. Derbyshire |
|
|
Adam C. Derbyshire |
|
|
Senior Vice President and Chief Financial Officer |